ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 156 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2015. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $9,881,000 | +2.1% | 789,210 | +12.9% | 0.00% | 0.0% |
| Q3 2016 | $9,678,000 | +48.9% | 698,775 | +6.2% | 0.00% | +100.0% |
| Q2 2016 | $6,500,000 | -36.6% | 657,919 | +8.5% | 0.00% | -50.0% |
| Q1 2016 | $10,253,000 | -21.8% | 606,342 | +3.0% | 0.00% | -33.3% |
| Q4 2015 | $13,109,000 | +77.3% | 588,889 | +87.9% | 0.00% | +50.0% |
| Q3 2015 | $7,394,000 | -71.2% | 313,457 | -0.1% | 0.00% | -66.7% |
| Q2 2015 | $25,662,000 | +48.4% | 313,865 | +68.1% | 0.01% | +50.0% |
| Q1 2015 | $17,288,000 | +144.8% | 186,692 | +6.9% | 0.00% | +100.0% |
| Q4 2014 | $7,063,000 | -5.6% | 174,651 | -42.9% | 0.00% | 0.0% |
| Q3 2014 | $7,483,000 | +55.1% | 305,927 | +0.4% | 0.00% | +100.0% |
| Q2 2014 | $4,825,000 | -1.0% | 304,627 | -5.5% | 0.00% | 0.0% |
| Q1 2014 | $4,874,000 | +18.7% | 322,343 | +7.9% | 0.00% | 0.0% |
| Q4 2013 | $4,106,000 | +70.4% | 298,837 | +133.8% | 0.00% | 0.0% |
| Q3 2013 | $2,410,000 | – | 127,801 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |